Drug Trial Radar · NCT05160415
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Dec 28, 2021
Primary completion
Mar 1, 2024
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Dec 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD). Sevasemten is an investigational product intended to protect and improve function of dystrophic muscle fibers.
Conditions
- Becker Muscular Dystrophy
Interventions
SevasemtenDrug
Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Treated With Sevasemten Experiencing AEsTime frame: From first dose of study drug to 25 months
- Frequency of AEs in Those Treated With SevasemtenTime frame: From first dose of study drug to 25 months
- Number of Participants Treated With Sevasemten With AEs by Maximum SeverityTime frame: From first dose of study drug to 25 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rare Disease Research
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.